Reinstatement of the Chinese endemic species Styrax zhejiangensis.

Styrax zhejiangensis has been treated as a synonym of S. macrocarpus. Examination of herbarium specimens and observation of wild living plants demonstrates that S. zhejiangensis is a distinct species and is clearly distinguishable from S. macrocarpus through its flowering phenology in which leaves and flowers open simultaneously, its smaller corolla lobes and filaments, and its white-stellate-pubescent seeds. On this basis, we reinstate S. zhejiangensis as an accepted species. Photographic images and a distribution map of the two species are provided. A lectotype of S. zhejiangensis is also designated.

[Development of clinical application and experimental reseach on prescription biejiajian wan].

We reviewed the modern development of clinical application and experimental reseach on the prescription Biejiajian Wan (BJ), which are the basement that we will study its anti-renal fibrosis. At present, the prescription BJ is mainly applied to the treatment of chronic heptic desease. Its experimental reseach is mainly confined to the studing of anti-heptic fibrosi. Refering the scientific and technological result of anti-heptic fibrosis, we think the prescription BJ would have the effection of anti-renal fibrosis on the basis of theory of planning treatment according to diagnosis. But it has not been reported to the prescription BJ on the clinical and experimental reseach on anti-renal fibrosis. Therefore, it is very important to take on clinical reseach of the prescription BJ and discuss the effecting mechanism of anti-renal fibrosis from the level of integration, cell and molecule, which will help to enlarge the clinical application of the prescription Biejiajianwan and explained the essence of "persistent diseases injuring collateral branch of large channel" in traditional Chinese medicine.